Home › Compare › BNOEF vs JNJ

BNOEF vs JNJ: Dividend Comparison 2026

BNOEF yields 33333.33% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BNOEF wins by $8.428195308647591e+21M in total portfolio value
10 years
BNOEF
BNOEF
● Live price
33333.33%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.428195308647591e+21M
Annual income
$8,378,748,509,141,157,000,000,000,000.00
Full BNOEF calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — BNOEF vs JNJ

📍 BNOEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBNOEFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BNOEF + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BNOEF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BNOEF
Annual income on $10K today (after 15% tax)
$2,833,333.33/yr
After 10yr DRIP, annual income (after tax)
$7,121,936,232,769,983,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, BNOEF beats the other by $7,121,936,232,769,983,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BNOEF + JNJ for your $10,000?

BNOEF: 50%JNJ: 50%
100% JNJ50/50100% BNOEF
Portfolio after 10yr
$4.2140976543237957e+21M
Annual income
$4,189,374,254,570,578,700,000,000,000.00/yr
Blended yield
99.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

BNOEF
No analyst data
Altman Z
-5.0
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BNOEF buys
0
JNJ buys
0
No recent congressional trades found for BNOEF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBNOEFJNJ
Forward yield33333.33% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$8.428195308647591e+21M$20.0K ✓
Annual income after 10y$8,378,748,509,141,157,000,000,000,000.00 ✓$827.78
Total dividends collected$8.424943808765552e+21M ✓$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BNOEF vs JNJ ($10,000, DRIP)

YearBNOEF PortfolioBNOEF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$3,344,033$3,333,333.33$10,676$355.77+$3.33M → BNOEF
2$1,045,333,048$1,041,754,932.50$11,407$389.39+$1045.32M → BNOEF
3$305,463,295,767$304,344,789,404.97$12,198$426.53+$305463.28M → BNOEF
4$83,443,192,327,233$83,116,346,600,762.75$13,056$467.62+$83443192.31M → BNOEF
5$21,308,754,850,592,396$21,219,470,634,802,260.00$13,987$513.12+$21308754850.58M → BNOEF
6$5,087,082,937,849,453,000$5,064,282,570,159,319,000.00$14,998$563.56+$5087082937849.44M → BNOEF
7$1,135,355,897,925,379,400,000$1,129,912,719,181,880,500,000.00$16,098$619.52+$1135355897925379.50M → BNOEF
8$236,895,694,937,506,160,000,000$235,680,864,126,726,020,000,000.00$17,295$681.69+$236895694937506176.00M → BNOEF
9$46,211,962,155,546,610,000,000,000$45,958,483,761,963,480,000,000,000.00$18,599$750.82+$46211962155546607616.00M → BNOEF
10$8,428,195,308,647,591,000,000,000,000$8,378,748,509,141,157,000,000,000,000.00$20,022$827.78+$8.428195308647591e+21M → BNOEF

BNOEF vs JNJ: Complete Analysis 2026

BNOEF — Stock

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Full BNOEF Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this BNOEF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BNOEF vs SCHDBNOEF vs JEPIBNOEF vs OBNOEF vs KOBNOEF vs MAINBNOEF vs ABBVBNOEF vs MRKBNOEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.